Previous 10 | Next 10 |
MINNEAPOLIS, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) is set to be a first mover in the artificial intelligence (AI) powered drug discovery market that POAI expects will grow to $20 billion in the next three years, reported the Company today in outlining its...
Point Roberts, WA and Vancouver, BC - January 14, 2022 (Investorideas.com Newswire) Investorideas.com ( www.investorideas.com ), a global investor news source covering Artificial Intelligence (AI) brings you today's edition of The AI Eye - watching stock news, deal tracker and advan...
Predictive Oncology (NASDAQ: POAI) , a knowledge-driven company focused on applying artificial intelligence (“AI”) to develop personalized cancer therapies, today reported the preliminary results of its Discovery 2021 program. According to the update, Predictive Oncologyȁ...
MINNEAPOLIS, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) reported the preliminary results of its Discovery 2021 program today, announcing that its Helomics subsidiary’s evaluation demonstrated their proprietary Artificial Intelligence (AI) program CoRE...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips I’ll begin this penny stock list in the same manner that I begin all lists of penny stocks: With a caveat. Penny stocks are among the most volatile classes of investments. Pretty much everyone interested in this...
Predictive Oncology (NASDAQ: POAI) , a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced a new time for its annual meeting of stockholders. The meeting was originally scheduled for Dec. 23, 2021, ...
MINNEAPOLIS, Dec. 27, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI) , a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced today that the Company’s Annual Meeting of S...
Predictive Oncology (NASDAQ: POAI) , a knowledge-driven company focused on applying artificial intelligence (“AI”) to develop personalized cancer therapies, today issued a year-end corporate update. Among the highlights, the update discussed POAI’s November 2021 acquisi...
EAGAN, Minn., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology , (POAI), a knowledge-driven company focused on applying artificial intelligence (AI) to develop personalized cancer therapies, is moving in the right direction. In November 2021, POAI acquired zPREDICTA, ...
Predictive Oncology (NASDAQ: POAI) , a knowledge-driven company focused on applying artificial intelligence (“AI”) to develop personalized cancer therapies, today announced that Pamela Bush, Ph.D., MBA will be joining the company’s leadership team as SVP of Strategic Sa...
News, Short Squeeze, Breakout and More Instantly...
Predictive Oncology Inc. Company Name:
POAI Stock Symbol:
NASDAQ Market:
Predictive Oncology Inc. Website:
Predictive Oncology (NASDAQ: POAI) , a leader in AI-driven drug discovery and biologics, today announced the introduction of a new technology designed to express functional and stable G-Protein Coupled Receptors (“GPCRs”). GPCRs are cell surface membrane receptors believed to play a...
Company files expansive intellectual property protection for “Membrane Protein Factory” to produce purified and biologically active membrane proteins for drug development External sources value annual US GPCR market at nearly $3.5 billion in 2022, growing more than 5% annu...
Predictive Oncology (NASDAQ: POAI) , a leader in AI-driven drug discovery and biologics, today announced the availability of its unique 3D cell culture model to advance cancer drug discovery and enable future drug development. More closely mimicking human tissue architecture than traditional 2D a...